Bonesupport Q3 revenue tops estimates on strong US sales growth
Sweden's Bonesupport reported Q3 revenue up 39% year on year, beating analyst expectations, according to Reuters based on LSEG data.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, Sweden's orthobiologics company Bonesupport Holding posted third-quarter revenue up 39% year on year, ahead of analyst forecasts. Revenue reached SEK 408.8 million against a consensus of SEK 389.33 million from three analysts.
The company said strong sales in the US drove the increase, with growth in Europe and the Rest of World also contributing. The CMS confirmed a DRG reassignment for CERAMENT G, which allows higher reimbursement for qualifying cases. Adjusted EPS was SEK 1.41, gross margin 92% and EBIT SEK 123.4 million. The company gave no guidance for future quarters or the full year, and it repurchased SEK 91.6 million of shares under its buyback program.
why it matters
The report matters for investors in the medtech and orthobiologics space. The average analyst rating is buy, and the median 12-month price target of SEK 361.75 sits about 40.6% above the October 21 close. The stock trades near 37 times forward earnings, up from 35 three months ago, so the market already prices in strong growth.
market impact
Bonesupport: revenue above forecasts supports the stock and the medtech sector
tags
instruments
sources
- Sweden's Bonesupport Q3 revenue beats estimates on US segment growth — Reuters, 22 October 2026 at 06:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗